Innoviva (INVA) Stock
Pharmaceutical royalty holder for respiratory and specialty drugs. Here's the price, business snapshot, and what's worth knowing about Innoviva in October 2026.
Innoviva, Inc. (INVA) is a small-cap company that primarily holds royalty and related commercialisation interests in respiratory and speciality pharmaceutical products. With a market capitalisation of about $1.10 billion, Innoviva’s profile is that of an asset-holder rather than an operating drug developer: it seeks to generate cash flow through royalty receipts, licensing agreements and selective investments. For investors this means revenue can be relatively predictable when royalties are stable, but performance depends on partner sales, patent expiries and regulatory outcomes beyond Innoviva’s direct control. The stock can suit those looking for exposure to pharmaceutical revenues without direct drug-development risk, yet it carries concentration and sector-specific risks. As with any investment, values can rise or fall, past payments are not a guarantee of future ones, and this summary is for educational purposes only — not personalised advice. Prospective investors should review company filings and consider how the firm fits their risk tolerance and time horizon.
Innoviva (INVA) Stock Forecast
Analyst price target, next 12 months
$37.00
+80.5% vs today's $20.50
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Innoviva have a consensus 12-month target of $37.00, above the current price of $20.50.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Innoviva's stock with a target price of $37, indicating significant growth potential.
Financial Health
Innoviva Inc. is performing well with strong revenue, profits, and cash flow indicators.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Royalty Income Model
Innoviva earns from product sales via royalties, which can deliver steady cash when partners perform — though revenues depend on third-party sales and can vary.
Market Exposure
Concentration in respiratory and speciality medicines links returns to a specific healthcare segment; regulatory or competitive shifts can materially affect outcomes.
Balance Sheet Focus
Investors often watch cash, dividend policy and capital allocation; strong financials can cushion volatility, but no outcome is guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
